Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

December 15, 2023

https://www.prnewswire.com/news-releases/curis-announces-initial-combination-study-data-from-its-takeaim-lymphoma-study-302012478.html

LEXINGTON, Mass., Dec. 12, 2023 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS lymphoma (PCNSL) patients.

Read more at prnewswire.com

Related news for (CRIS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.